Email Updates

Search form

You are here

Multipurpose Prevention Technologies

HIV prevention and women’s reproductive health go hand in hand.

HIV prevention doesn’t happen in isolation. Even when people are at high risk for HIV, avoiding infection is but one factor in a complex set of decisions about their health and well-being. For women worldwide, those decisions include childbearing and reproductive and sexual health.

Multi-purpose prevention technologies are now in development to simultaneously prevent unintended pregnancy and protect against HIV and other sexually transmitted infections. By addressing multiple health concerns in convenient, easy-to-use formulations, these technologies might also help ensure high levels of product adherence. Multiple versions are entering early clinical trials now. Many important questions about efficacy, acceptability and adherence need to be addressed as this research proceeds.

What We're Reading

This article outlines a strategic action framework developed as an outcome of a series of expert meetings held between 2014 and 2016. The meetings focused on identifying opportunities and challenges for MPTs that combine hormonal contraception (HC) with antiretroviral drugs into single products.

September 24, 2018
The European Journal of Contraception & Reproductive Health

A novel combination tenofovir/levonorgestrel ring, as well as a tenofovir-only ring, are currently in expanded clinical development.

August 1, 2018
IMPT

A new Phase I study of the Population Council’s multipurpose prevention technology (MPT) gel PC-1005, launching this week, will examine the safety of the gel when used rectally by both men and women. If proven effective, PC-1005 gel would be the first product to prevent three incurable sexually transmitted infections (STIs)—HIV, herpes simplex virus (HSV), and human papillomavirus (HPV).

June 21, 2018
Population Council
Subscribe to RSS - Multipurpose Prevention Technologies